Pancreatic Cancer Finally Lands a Hit as GI Oncology Shifts at ASCO 2026

Gastrointestinal cancers — encompassing tumors of the colon, rectum, stomach, pancreas, liver, and bile ducts — collectively represent the most common cause of cancer death worldwide. Progress has been uneven. Colorectal cancer has benefited substantially from targeted therapies and improved screening; pancreatic cancer has resisted nearly everything. Gastric cancer has seen immunotherapy take hold in HER2-positive and PD-L1-high subgroups, but the majority of patients still progress within months of first-line treatment.

ASCO 2026 brings a remarkable convergence of data across GI malignancies. The five trials below span tumors from the colon to the pancreas, address questions from the early-stage setting to the metastatic, and share a common thread: the growing role of molecular targeting in diseases that, until recently, were treated largely the same way for every patient.

Pancreatic Cancer Finally Gets a Serious KRAS Shot

Late-Breaking Abstract LBA5 | Trial: NCT06625320

Pancreatic ductal adenocarcinoma (PDAC) has been one of oncology’s most stubborn problems. Approximately 90% of cases carry a mutation in the KRAS gene — a molecular switch that becomes permanently stuck in the “on” position, driving uncontrolled cell growth. For decades, KRAS was considered undruggable: its smooth protein surface offered no pocket for drug molecules to bind. Chemotherapy remained the only option for second-line treatment, and it rarely extended survival by more than a few weeks.

Daraxonrasib (RMC-6236) is a pan-RAS inhibitor — a drug designed to block all RAS-mutant proteins simultaneously by occupying a newly discovered binding site shared across KRAS variants. RASolute 302 randomizes patients with previously treated metastatic PDAC to daraxonrasib versus standard chemotherapy. Topline results previewed before the meeting reveal a near-doubling of median overall survival compared to chemotherapy — results oncologists across the field have described as the most significant advance in PDAC in over a decade. The full data, including the survival curves, response rates, and safety profile, are presented at the ASCO plenary session — the meeting’s highest-profile slot, reserved for trials with potential to immediately change global practice.

Why it matters: If the full data confirm the topline signal, daraxonrasib becomes the first RAS-targeted therapy to demonstrate an overall survival benefit in PDAC — establishing a new second-line standard for a disease where chemotherapy has been the ceiling for twenty years, and validating the pan-RAS inhibition strategy for future first-line combinations.

A Hard-to-Treat Colon Cancer Subtype Moves Toward Targeted First-Line Care

Late-Breaking Abstract LBA3503 | Trial: NCT04607421

Approximately 10–15% of metastatic colorectal cancer patients carry the BRAF V600E mutation — a single DNA change that permanently activates a growth-signaling protein called BRAF. This mutation is associated with a particularly aggressive disease course, with patients historically surviving a median of 12–18 months from metastatic diagnosis. The BEACON CRC trial demonstrated that combining the BRAF inhibitor encorafenib with the EGFR antibody cetuximab improves survival after prior treatment. BREAKWATER now asks whether deploying this targeted doublet in the first-line setting — alongside FOLFIRI chemotherapy — produces an even more substantial benefit.

The ASCO 2026 presentation delivers progression-free and overall survival data from Cohort 3 of BREAKWATER, comparing encorafenib plus cetuximab plus FOLFIRI against standard first-line chemotherapy regimens. This is the most anticipated colorectal cancer readout in years, bringing the targeted strategy — already proven in second-line disease — to the front of treatment for the subtype with the worst prognosis.

Why it matters: BRAF V600E colorectal cancer is the subtype oncologists approach most urgently at diagnosis. A confirmed overall survival benefit with the triplet targeted regimen upfront would rewrite first-line treatment guidelines for this population and establish BRAF/EGFR-targeted therapy as the default starting point — rather than something tried after chemotherapy fails.

The Colon Cancer Chemotherapy Decision May Soon Start With a Blood Test

Late-Breaking Abstract LBA3500 | Trial: NCT04089631

For patients with stage II colon cancer — meaning the tumor has grown through the colon wall but has not spread to lymph nodes or distant organs — the decision about whether to administer chemotherapy after surgery is among the most contested in gastrointestinal oncology. Standard staging tools (imaging, pathology) are imprecise predictors of recurrence risk, leading to either overtreatment (unnecessary chemotherapy with significant toxicity) or undertreatment (missed opportunity to eradicate microscopic disease).

Circulating tumor DNA (ctDNA) offers a different lens. ctDNA is DNA shed by cancer cells into the bloodstream, detectable by blood draw after surgery. Its presence indicates that microscopic disease persists despite surgery; its absence suggests the patient may be cured. CIRCULATE is a phase 3 trial that uses ctDNA detection after resection to guide adjuvant chemotherapy decisions in stage II colon cancer — giving chemotherapy to ctDNA-positive patients and withholding it from ctDNA-negative patients. The trial tests whether this biomarker-guided strategy produces better overall outcomes than traditional clinicopathologic risk stratification.

Why it matters: ctDNA-guided therapy represents a fundamental shift in how adjuvant decisions are made — moving from population-level risk estimates to individual-level molecular evidence. A positive CIRCULATE result would accelerate the adoption of post-surgical ctDNA testing as standard practice and reduce unnecessary chemotherapy for the majority of stage II colon cancer patients who are likely cured by surgery alone.

One of Immunotherapy’s Toughest Colon Cancer Challenges Returns

Abstract 3504 | Trial: NCT05308446

As BREAKWATER defines the first-line standard for BRAF V600E colorectal cancer, SWOG S2107 asks the next question: can adding an immunotherapy agent to the targeted doublet do even more? The majority of BRAF V600E colorectal cancers are microsatellite stable (MSS) — meaning they lack the DNA repair defects that typically make colorectal cancers responsive to immunotherapy. MSS tumors have been largely resistant to checkpoint inhibitors used alone. The hypothesis in SWOG S2107 is that BRAF-targeted therapy changes the tumor microenvironment in ways that make it immunologically vulnerable, potentially sensitizing it to nivolumab.

This randomized phase 2 trial tests encorafenib plus cetuximab versus encorafenib plus cetuximab plus nivolumab in previously treated MSS BRAF V600E metastatic colorectal cancer. Alongside the efficacy data, the trial collects deep molecular profiling — looking for the MAPK signaling and immune activation patterns that prior non-randomized data suggested characterize responders — to define who benefits from the immune addition.

Why it matters: If the triplet outperforms the doublet, it opens the door to immunotherapy in one of the last colorectal cancer populations where checkpoint inhibitors have had no clear role. The molecular profiling data may be equally valuable — potentially identifying a biomarker subset of MSS BRAF V600E patients for whom immunotherapy is genuinely active.

Liver Cancer’s Old Standard Meets the Immunotherapy Era

Late-Breaking Abstract LBA4000 | Trial: NCT04104074

Hepatocellular carcinoma (HCC) — the most common form of liver cancer — presents a layered treatment challenge. Patients who are eligible for locoregional therapy, meaning tumor-directed treatment delivered directly into the liver, occupy a middle ground: their disease has not spread systemically, but it cannot be surgically removed. Transarterial chemoembolization (TACE) — blocking the blood vessels feeding the tumor and delivering chemotherapy locally — has been the standard approach for decades. Systemic immunotherapy has transformed outcomes in more advanced disease, but its role combined with TACE has been uncertain.

EMERALD-3 is a phase 3 trial testing the combination of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) with or without lenvatinib alongside TACE, versus TACE alone, in patients with unresectable but embolization-eligible HCC. The dual checkpoint approach — blocking two separate immune inhibitory pathways simultaneously — is designed to amplify the immune response triggered when TACE destroys tumor tissue and releases tumor antigens. The primary endpoint is progression-free survival.

Why it matters: TACE has been a standard for intermediate-stage HCC for over two decades without being substantially improved upon. A positive EMERALD-3 result would represent the first systemic immunotherapy combination to demonstrate benefit in this locoregional-eligible population — integrating systemic immune activation with local tumor control for the first time.

The Bigger Picture in GI Oncology at ASCO 2026

The defining theme across GI cancers at this meeting is molecular precision arriving in settings where it has been absent. RASolute 302 proves that KRAS-driven pancreatic cancer — long considered untargetable — can be disrupted by the right drug. BREAKWATER and SWOG S2107 together define not just the new standard for BRAF V600E colorectal cancer, but whether immunotherapy has any role in the MSS subtype. CIRCULATE challenges the traditional paradigm of adjuvant chemotherapy decisions with a blood-based biomarker approach that could eventually extend to other early-stage GI malignancies. And EMERALD-3 asks whether the immunological revolution in HCC — already established in systemic disease — can be carried into the locoregional-eligible population.

Author

Bernice Lottering